Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 1 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Rare protective or risk variant (APOE3 Christchurch, APOE R145C, RELN, FN1) Genes (not modifiable) | Prevention |
No direction reported
whyAmong 37 heterozygous carriers (ages 56.6-82.1) none had developed AD or MCI by the March 2022 data freeze and apolipoprotein B was lower than in non-carriers, but the authors say continued follow-up is necessary and no homozygotes were found, so protection could not be tested. No incidence comparison is reported, so no direction is recorded. |
Alzheimer's disease or MCI diagnoses and blood lipid biomarkers in heterozygous APOE Christchurch carriers | cohort study | 455,306 | not established — research letter with no pubmed abstract; the full text at pmc10685495 reports carrier counts and p-values (apob p = 0.004; p = 0.036… |
Molecular Neurodegeneration
2023 ✓ Peer-reviewed PMID 38017580 |